1 |
<p align="center"><b>PLIVA finalises acquisition of majority stake in LACHEMA, |
2 |
Czech pharmaceutical company</b></p> |
3 |
<p>Zagreb, December 3, 1999</p> |
4 |
<p>PLIVA today announced that the acquisition of 66,67% stake of the Czech pharmaceutical |
5 |
company, Lachema, was completed yesterday when PLIVA Krakow, PLIVAs subsidiary |
6 |
paid agreed price of USD 26.5 million. Completion follows the agreement that |
7 |
was reached between PLIVA Krakow and Czech institutional investors as announced |
8 |
on 12 November 1999.</p> |
9 |
<p>Lachema is one of the leading Czech pharmaceutical companies. It develops, |
10 |
manufactures and markets pharmaceuticals as well as diagnostic preparations |
11 |
and fine chemicals. Lachemas strength lies in cytostatics. Also, cardiovascular |
12 |
drugs and antivirotics complete the companys current portfolio. Lachemas range |
13 |
of generic cytostatic products and its brand new facility for injectable cytostatics |
14 |
will enable PLIVA to continue its further expansion into this attractive niche |
15 |
market, not only in the CEE region, but into Western markets as well. </p> |